The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 4, 2006, Pages 243-246

  Negro, Roberto ^a   Hassan, Haslinda ^b  

^a AUSL LE/1   (Italy)

^b RIPAS HOSPITAL   (Brunei Darussalam)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Diabetes; Hypertension

Indexed keywords

ADIPONECTIN; AMLODIPINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; TELMISARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MIDDLE AGED; PPAR GAMMA;

EID: 33847745825     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.045     Document Type: Article

References (29)

1. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995;13:1457-62.
2. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996;125:304-10.
3. UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 1998;317:703-17.
4. Ersoy C, Imamoglu S, Budak F, Tuncel E, Eruk E, Oral B. Effect of amlodipine on insulin resistance and tumor necrosis factor-alpha in hypertensive obese type 2 diabetic patients. Indian J Med Res 2004;120:481-8.
5. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999;12:298-303
6. Harano Y, Kageyama A, Hirose J et al. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 1995;44:315-19.
7. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydro-epiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive me. J Clin Endocrinol Metab 1993;76:1464-9.
8. Yusuf S, Gerstein H, Hoogwerf B et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.
9. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertens 2003;42:76-81.
10. Benson C, Pershadsing HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activit. Hypertens 2004;43:993-1002.
11. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-53.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-call function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
13. Miyazaki Y, Murakami H, Hirata A et al. Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients. Am J Hypertens 1998;11:962-70.
14. Iimura O, Shimamoto K, Matsuda K et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995;8:353-7.
15. Folli F, Saad MJ, Velloso L et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999;107:133-9.
16. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration, Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990;13:1109-11.
17. Higashiura K, Ura N, Takada T et al. The effect of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000;13:290-7.
18. Togashi N, Ura N, Higashiura K, Murakami H, Simamoto K. The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000;18:1605-10.
19. Bogan JS, Lodish HF. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol 1999; 146:609-20.
20. Maeda N, Takahashi M, Funahashi T et al. PPARγ ligands increase expression and plasma concentrations of adipon-ectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
21. Rosen E, Sarraf P, Troy AEet al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-17.
22. Tan KC, Xu A, Chow WS et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilatation. J Clin Endocrinol Metab 2004;89:765-9.
23. Ueshiba H, Miyachi Y, Effects of the long-acting calcium channel blockers amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 2004;43:561-5.
24. Yildiz A, Hursit M, Celik AV et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol 2002;58:405-10
25. De Courten M, Ferrari P, Schneider M et al. Lack of effect on long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 1993;44:457-62.
26. Baron AD, Brechtel GB, Wallace P, Edelman SV Rates and tissue sites on non-insulin and insulin-mediated glucose uptake in humans, Am J Physiol 1998;255:E769-E774.
27. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman MA. Possible role of cytosolic free calcium concentration in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 1988;82:1848-52.
28. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double blind, placebo-controlled 12-month study. Hypertens Res 2004;27:457-64.
29. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005;28:498.